Publications
- Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes2023 | Third Faculty of Medicine, Faculty of Medicine in Hradec Králové, Central Library of Charles University
- Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial2023 | Third Faculty of Medicine, Central Library of Charles University
- Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial2023 | Third Faculty of Medicine, Central Library of Charles University
- Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration A Randomized Clinical Trial2021 | Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Letter to the Editor from Brunerová et al: "Association of Cognitive Function and Retinal Neural and Vascular Structure in Type 1 Diabetes"2021 | Third Faculty of Medicine, Faculty of Arts
- Clinical variables associated with failure of retinal detachment repair: the European vitreo-retinal society retinal detachment study report number 42014 | Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Incidence of adverse events after loading phase of the brolucizumab therapy of neovascular AMD: Real-life evidence in the Czech Republic2023 | Third Faculty of Medicine, Faculty of Medicine in Hradec Králové, Central Library of Charles University, First Faculty of Medicine
- Diabetic Macular Edema - Diagnostics and Treatment Guidelines2023 | Third Faculty of Medicine, Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Laser Vitreolysis for Vitreous Opacities: A Prospective Study2023 | Third Faculty of Medicine
- Vitreoretinal surgery2022 | Faculty of Medicine in Pilsen, Third Faculty of Medicine, First Faculty of Medicine
Loading network view...